Sight Sciences, Inc. (SGHT)

NASDAQ: SGHT · IEX Real-Time Price · USD
9.71
-0.10 (-1.02%)
Aug 12, 2022 4:00 PM EDT - Market closed
-1.02%
Market Cap 462.10M
Revenue (ttm) 59.90M
Net Income (ttm) -80.21M
Shares Out 47.59M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 586,881
Open 9.22
Previous Close 9.81
Day's Range 8.41 - 9.89
52-Week Range 6.25 - 39.73
Beta n/a
Analysts Buy
Price Target 14.79 (+52.3%)
Earnings Date Aug 11, 2022

About SGHT

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to... [Read more...]

Industry Medical Devices
IPO Date Jul 15, 2021
Employees 212
Stock Exchange NASDAQ
Ticker Symbol SGHT
Full Company Profile

Financial Performance

In 2021, Sight Sciences's revenue was $48.96 million, an increase of 77.12% compared to the previous year's $27.64 million. Losses were -$62.96 million, 81.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for SGHT stock is "Buy." The 12-month stock price forecast is 14.79, which is an increase of 52.32% from the latest price.

Price Target
$14.79
(52.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Sight Sciences (SGHT) Might Surprise This Earnings Season

Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Wall Street Analysts Believe Sight Sciences, Inc. (SGHT) Could Rally 121%: Here's is How to Trade

The consensus price target hints at a 121.5% upside potential for Sight Sciences, Inc. (SGHT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Sight Sciences, Inc. (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bears are Losing Control Over Sight Sciences, Inc. (SGHT), Here's Why It's a 'Buy' Now

Sight Sciences, Inc. (SGHT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement a...

Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve p...

Wall Street Analysts See a 200% Upside in Sight Sciences, Inc. (SGHT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 199.7% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable...

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

MENLO PARK, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve p...

Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Sur...

MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve ...

Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022

MENLO PARK, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve...

Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results

MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care...

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pse...

Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject® in lowering intraocular pressure (IOP) as a standalone treatment option without conc...

Sight Sciences Announces Appointment of Brenda Becker to Board of Directors

Legislative and health policy expert brings extensive private and public sector experience Legislative and health policy expert brings extensive private and public sector experience

Sight Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

MENLO PARK, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve...

Sight Sciences to Participate in the Upcoming Citi Virtual Healthcare Conference

MENLO PARK, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care...

Sight Sciences Launches “Don't Wait for Too Late” Awareness Campaign for Glaucoma

Educational campaign aims to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma Educational campaign aims to ra...

Why Earnings Season Could Be Great for Sight Sciences (SGHT)

Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results

MENLO PARK, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care ...

FDA Approves Sight Sciences' TearCare System For Common Eye Condition

The FDA has cleared Sight Sciences Inc's (NASDAQ: SGHT) TearCare System for meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED).  The indication clears TearCare for applying lo...

Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference

MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care...

FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure

The FDA has signed off Sight Sciences Inc's (NASDAQ: SGHT) clinical study to assess investigational higher volume OMNI device to perform canal viscodilation alone to lower intraocular pressure (IOP) in ...

Sight Sciences Reports Third Quarter 2021 Financial Results

MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care ...

Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled...

As the pioneer of ab interno canaloplasty, Sight Sciences is executing this IDE trial to seek FDA clearance for canal viscodilation alone as a MIGS procedure for adults with POAG As the pioneer of ab in...

Wall Street Analysts Predict a 73% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 72.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable,...

Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market close...

Wall Street Analysts See a 68% Upside in Sight Sciences, Inc. (SGHT): Can the Stock Really Move This High?

The mean of analysts' price targets for Sight Sciences, Inc. (SGHT) points to a 67.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo...